Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Catalyst Pharmaceutical Partners (CPRX)
:CPRX
Holding CPRX?
Track your performance easily
CPRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$13.12 - $24.27
Previous CloseN/A
Volume328.11K
Average Volume (3M)944.16K
Market Cap
$2.72B
Enterprise Value$2.05B
Total Cash (Recent Filing)$40.41M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)19.5
Beta1.10
Next Earnings
Mar 12, 2025EPS Estimate
0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.17
Shares Outstanding119,273,440
10 Day Avg. Volume1,026,361
30 Day Avg. Volume944,156
Standard Deviation0.14
R-Squared0.09
Alpha0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)5.91
Price to Cash Flow (P/CF)9.30
P/FCF Ratio9.40
Enterprise Value/Market Cap0.76
Enterprise Value/Revenue4.46
Enterprise Value/Gross Profit5.93
Enterprise Value/Ebitda8.91
Forecast
1Y Price Target
$31.83Price Target Upside39.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Catalyst Pharma News
Ownership Overview
6.30% Insiders
17.43% Mutual Funds
0.10% Other Institutional Investors
49.15% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CPRX FAQ
What was Catalyst Pharmaceutical Partners’s price range in the past 12 months?
Catalyst Pharmaceutical Partners lowest stock price was $13.12 and its highest was $24.27 in the past 12 months.
What is Catalyst Pharmaceutical Partners’s market cap?
Catalyst Pharmaceutical Partners’s market cap is $2.72B.
When is Catalyst Pharmaceutical Partners’s upcoming earnings report date?
Catalyst Pharmaceutical Partners’s upcoming earnings report date is Mar 12, 2025 which is in 61 days.
How were Catalyst Pharmaceutical Partners’s earnings last quarter?
Catalyst Pharmaceutical Partners released its earnings results on Nov 06, 2024. The company reported $0.35 earnings per share for the quarter, beating the consensus estimate of $0.304 by $0.046.
Is Catalyst Pharmaceutical Partners overvalued?
According to Wall Street analysts Catalyst Pharmaceutical Partners’s price is currently Undervalued.
Does Catalyst Pharmaceutical Partners pay dividends?
Catalyst Pharmaceutical Partners does not currently pay dividends.
What is Catalyst Pharmaceutical Partners’s EPS estimate?
Catalyst Pharmaceutical Partners’s EPS estimate is 0.35.
How many shares outstanding does Catalyst Pharmaceutical Partners have?
Catalyst Pharmaceutical Partners has 119,273,440 shares outstanding.
What happened to Catalyst Pharmaceutical Partners’s price movement after its last earnings report?
Catalyst Pharmaceutical Partners reported an EPS of $0.35 in its last earnings report, beating expectations of $0.304. Following the earnings report the stock price went up 2.378%.
Which hedge fund is a major shareholder of Catalyst Pharmaceutical Partners?
Among the largest hedge funds holding Catalyst Pharmaceutical Partners’s share is Deerfield Management Company, LP. It holds Catalyst Pharmaceutical Partners’s shares valued at 124M.
---
Catalyst Pharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$31.83 (39.61% Upside)
$31.83 (39.61% Upside)
Blogger Sentiment
Bullish
CPRX Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 3.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.3%
Last 30 Days ▼ 5.0%
Last 30 Days ▼ 5.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
50.89%
12-Months-Change
Fundamentals
Return on Equity
28.29%
Trailing 12-Months
Asset Growth
86.83%
Trailing 12-Months
Company Description
Catalyst Pharmaceutical Partners
Catalyst Pharmaceuticals is a biopharmaceutical company, which engages in the development and commercialization of therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, spinal muscular atrophy (SMA) type 3, and infantile spasmsThe company was founded Huckel E. Hubert in January 2002 and is headquartered in Coral Gables, FL.
---
CPRX Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented strong financial performance and positive growth, particularly with FIRDAPSE and AGAMREE. Despite a decline in FYCOMPA revenues and increased SG&A expenses, the company's overall financial position and strategic initiatives, including global expansion efforts, indicate a positive outlook.Read More>---
CPRX Stock 12 Month Forecast
Average Price Target
$31.83
▲(39.61% Upside)
Technical Analysis
Amgen
―
BioMarin Pharmaceutical
―
Regeneron
―
Vertex Pharmaceuticals
―
Ultragenyx Pharmaceutical
―
Best Analysts Covering CPRX
1 Year
1 Year Success Rate
16/19 ratings generated profit
1 Year Average Return
+31.86%
reiterated a buy rating 11 months ago
Copying Charles Duncan's trades and holding each position for 1 Year would result in 84.21% of your transactions generating a profit, with an average return of +31.86% per trade.
---